Skip to main content
Psilocybin IntoxicationPsychedelicsCognitive functionDrugPhase 1

What this study is

This study will evaluate the subjective and behavioral effects of psilocybin relative to placebo and alcohol.

What's being tested

  • 0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink

    Intervention · DRUG

    Participants will self-administer a capsule containing 0mg psilocybin and a drink that contains alcohol dosed to 0.00% BAC.

  • 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink

    Intervention · DRUG

    Participants will self-administer a capsule containing 1mg psilocybin and a drink that contains alcohol dosed to 0.00% BAC.

  • 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink

    Intervention · DRUG

    Participants will self-administer a capsule containing 5mg psilocybin and a drink that contains alcohol dosed to 0.00% BAC.

  • 15mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink

    Intervention · DRUG

    Participants will self-administer a capsule containing 15mg psilocybin and a drink that contains alcohol dosed to 0.00% BAC.

  • 25mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink

    Intervention · DRUG

    Participants will self-administer a capsule containing 25mg psilocybin and a drink that contains alcohol dosed to 0.00% BAC.

  • 0mg Psilocybin Capsule + 0.08% BAC Alcoholic Drink

    Intervention · DRUG

    Participants will self-administer a capsule containing 0mg psilocybin and a drink that contains alcohol dosed to 0.08% BAC.

Study details

Sponsor
Johns Hopkins University
Conditions
Psilocybin Intoxication
Enrolling
80 people
Starts
2027-03-01
Est. completion
2030-06-30
Design
Quadruple-blind, randomized, crossover, Phase 1
Record
View on ClinicalTrials.gov ↗